These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24674108)

  • 21. Management of excessive anticoagulant effect due to vitamin K antagonists.
    Dentali F; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2008; ():266-70. PubMed ID: 19074094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin.
    Crowther MA; Donovan D; Harrison L; McGinnis J; Ginsberg J
    Thromb Haemost; 1998 Jun; 79(6):1116-8. PubMed ID: 9657434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intentional low-molecular-weight heparin overdose: a case report and review.
    Byrne M; Zumberg M
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):772-4. PubMed ID: 23135382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing bleeding in anticoagulated patients in the emergency care setting.
    Pollack CV
    J Emerg Med; 2013 Sep; 45(3):467-77. PubMed ID: 23786779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10.
    Gunther KE; Conway G; Leibach L; Crowther MA
    Thromb Res; 2004; 113(3-4):205-9. PubMed ID: 15140584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate.
    Woo CH; Patel N; Conell C; Rao VA; Faigeles BS; Patel MC; Pombra J; Akins PT; Axelrod YK; Ge IY; Sheridan WF; Flint AC
    World Neurosurg; 2014 Jan; 81(1):110-5. PubMed ID: 23220122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding.
    Stewart WS; Pettit H
    Am J Emerg Med; 2013 Aug; 31(8):1251-4. PubMed ID: 23763937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Budget impact analysis of warfarin reversal therapies among hip fracture patients in Finland.
    Purmonen T; Törmälehto S; Säävuori N; Kokki H
    Drugs R D; 2015 Mar; 15(1):155-62. PubMed ID: 25749804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy.
    Shields RC; McBane RD; Kuiper JD; Li H; Heit JA
    Mayo Clin Proc; 2001 Mar; 76(3):260-6. PubMed ID: 11243272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and effectiveness of low dose oral vitamin K1 administration in asymptomatic out-patients on warfarin or acenocoumarol with excessive anticoagulation.
    Poli D; Antonucci E; Lombardi A; Gensini GF; Abbate R; Prisco D
    Haematologica; 2003 Feb; 88(2):237-8. PubMed ID: 12604423
    [No Abstract]   [Full Text] [Related]  

  • 31. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting.
    Tsu LV; Dienes JE; Dager WE
    Ann Pharmacother; 2012 Dec; 46(12):1617-26. PubMed ID: 23249867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correction of coagulopathy in warfarin associated cerebral hemorrhage.
    Aiyagari V; Testai FD
    Curr Opin Crit Care; 2009 Apr; 15(2):87-92. PubMed ID: 19300085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa.
    Kaku S; Suzuki M; Saitoh M; Funatsu T; Uemura T; Suzuki K; Iwatsuki Y; Kawasaki T
    Thromb Res; 2013 May; 131(5):450-6. PubMed ID: 23591155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
    Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
    Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversing anticoagulants both old and new.
    Warkentin TE; Crowther MA
    Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review on the Reversal of the Old and New Anticoagulants.
    Bailey AM; Blackburn MC; Crowley JM; Horn KS; Schultz AE; Justice SB
    Adv Emerg Nurs J; 2016; 38(4):279-294. PubMed ID: 27792070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of asymptomatic over-anticoagulation with oral vitamin K.
    Chirputkar SK; Poole HJ; McNeil RC; Tansey P; Etherington AM; Morrison C; Tait RC
    Br J Haematol; 2006 Nov; 135(4):591-2. PubMed ID: 17054668
    [No Abstract]   [Full Text] [Related]  

  • 38. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin.
    Chapman SA; Irwin ED; Beal AL; Kulinski NM; Hutson KE; Thorson MA
    Ann Pharmacother; 2011 Jul; 45(7-8):869-75. PubMed ID: 21775690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Splenic Infarction after Warfarin Overdose Treatment: Is It a Coincidence or Complication?
    Yılmaz G
    Ann Vasc Surg; 2019 Aug; 59():314.e5-314.e7. PubMed ID: 31009721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII.
    Taketomi T; Szlam F; Levy JH; Tanaka KA
    Blood Coagul Fibrinolysis; 2008 Jan; 19(1):106-8. PubMed ID: 18180627
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.